FDA Scrutinizes Rising Testosterone Prescriptions for Menopausal Women

The Food and Drug Administration is convening a public meeting to examine a medical practice that has grown quietly but steadily over the past few years: prescribing testosterone to women experiencing menopause. The move signals that federal regulators have begun to take notice of a trend that sits at the intersection of expanding clinical interest, pharmacy access problems, and fundamental uncertainty about whether the treatment actually works.

Testosterone prescriptions for menopausal women have been rising. The exact numbers remain somewhat opaque—this is not a formally approved use, and much of the prescribing happens off-label, meaning doctors are using an existing drug for a purpose the FDA never formally cleared it for. But the pattern is clear enough that it has caught the attention of multiple stakeholders: the regulatory agency itself, pharmacy chains that fill prescriptions, and the medical experts who study menopause and hormone therapy. Some women report that their doctors have recommended testosterone to address symptoms like low energy, diminished sexual desire, and mood changes that can accompany the menopausal transition. Others have found their prescriptions delayed or denied by pharmacies, creating a gap between what their physicians prescribed and what they could actually obtain.

The clinical case for testosterone in menopause remains contested. Proponents argue that some women experience a genuine decline in testosterone production during this life stage and that supplementing it can improve quality of life and sexual function. Critics point out that the long-term safety data is thin, that the condition itself is not formally recognized in regulatory terms, and that the evidence base for benefit is smaller and less rigorous than it is for other hormone therapies. The medical community has not reached consensus. Some gynecologists and menopause specialists have begun offering it; others remain skeptical or cautious. Insurance companies and pharmacy benefit managers have added another layer of friction by questioning whether the treatment is medically necessary, leading to denials and delays that leave patients and doctors frustrated.

Pharmacy access has emerged as a practical problem distinct from the scientific one. Women whose doctors have written prescriptions report that their local pharmacies cannot fill them, or can only do so after extended delays and appeals. Some pharmacies cite supply constraints or uncertainty about whether they should be dispensing a medication for an off-label indication. Others point to internal policies that require additional review before approving such prescriptions. The result is that even women whose physicians believe testosterone is appropriate for them may struggle to actually receive it.

The FDA's decision to hold a public meeting represents an acknowledgment that the agency needs more information before deciding whether to act. The meeting will likely include testimony from physicians who prescribe testosterone for menopausal women, researchers who study the therapy, patient advocates, pharmacy representatives, and other stakeholders. The agency may be considering whether to issue new guidance, whether to encourage formal clinical trials to establish safety and efficacy, or whether to take a more restrictive stance. What remains unclear is whether the FDA will ultimately view testosterone for menopause as a reasonable therapeutic option that simply needs better evidence and clearer standards, or as a practice that has outpaced the science and should be curtailed. The meeting itself signals that the status quo—rising prescriptions, inconsistent access, and unresolved clinical questions—is no longer acceptable to federal regulators.